Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: The examining pagoclone for persistent developmental stuttering study

Gerald Maguire, David Franklin, Nick G. Vatakis, Elena Morgenshtern, Timothey Denko, J. Scott Yaruss, Crystal Spotts, Larry Davis, Aaron Davis, Peter T Fox, Poonam Soni, Michael Blomgren, Andrew Silverman, Glyndon Riley

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

INTRODUCTION: Stuttering is a speech disorder in which the flow of speech is disrupted by repetitions, prolongation, and blocks of sounds, syllables, or words. No pharmacological treatments are approved for use in stuttering, and the most common form of treatment is speech therapy. This study was designed to assess the safety, tolerability, and effectiveness of pagoclone during 8 weeks of double-blind treatment followed by a 1-year open-label extension in patients who stutter. METHODS: An 8-week, multicenter, parallel-group, 2-arm, randomized (ratio 2:1 pagoclone-placebo), double-blind study with a 1-year open-label extension conducted at 16 US centers, including men and women aged 18 to 65 years who developed stuttering before 8 years of age. Twice-daily dosing with pagoclone (n = 88 patients) or matching placebo (n = 44 patients), with primary and secondary efficacy variables defined a priori, including Stuttering Severity Instrument Version 3 outcomes, clinician global impressions of improvement, and the change in the percentage of syllables stuttered. RESULTS: Pagoclone produced an average 19.4% reduction in percentage of syllables stuttered compared with 5.1% reduction for placebo. During open-label treatment, a 40% reduction in the percent syllables stuttered was observed after 1 year of treatment with pagoclone. The most commonly reported adverse event during double-blind treatment was headache (12.5% pagoclone patients, 6.8% placebo patients). DISCUSSION: Pagoclone was effective in reducing symptoms of stuttering and was well tolerated. In light of its favorable tolerability profile, as well as consistency of effects across multiple efficacy variables, pagoclone may have potential as a pharmacological treatment of stuttering. LIMITATIONS: The main limitation of this study was the adequacy of the number of subjects who participated because this study was conducted as a pilot investigation. Furthermore, as this condition waxes and wanes, the assessment of stuttering within the clinic setting may not be an adequate reflection of the stuttering of the patients within the community.

Original languageEnglish (US)
Pages (from-to)48-56
Number of pages9
JournalJournal of Clinical Psychopharmacology
Volume30
Issue number1
DOIs
StatePublished - Feb 2010

Fingerprint

Stuttering
Placebos
Therapeutics
Pharmacology
Speech Therapy
Speech Disorders
Clinical Studies
pagoclone
Waxes
Double-Blind Method
Headache
Safety

Keywords

  • Clinical trial
  • Pagoclone
  • Percent syllables stuttered
  • Stuttering

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Exploratory randomized clinical study of pagoclone in persistent developmental stuttering : The examining pagoclone for persistent developmental stuttering study. / Maguire, Gerald; Franklin, David; Vatakis, Nick G.; Morgenshtern, Elena; Denko, Timothey; Yaruss, J. Scott; Spotts, Crystal; Davis, Larry; Davis, Aaron; Fox, Peter T; Soni, Poonam; Blomgren, Michael; Silverman, Andrew; Riley, Glyndon.

In: Journal of Clinical Psychopharmacology, Vol. 30, No. 1, 02.2010, p. 48-56.

Research output: Contribution to journalArticle

Maguire, G, Franklin, D, Vatakis, NG, Morgenshtern, E, Denko, T, Yaruss, JS, Spotts, C, Davis, L, Davis, A, Fox, PT, Soni, P, Blomgren, M, Silverman, A & Riley, G 2010, 'Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: The examining pagoclone for persistent developmental stuttering study', Journal of Clinical Psychopharmacology, vol. 30, no. 1, pp. 48-56. https://doi.org/10.1097/JCP.0b013e3181caebbe
Maguire, Gerald ; Franklin, David ; Vatakis, Nick G. ; Morgenshtern, Elena ; Denko, Timothey ; Yaruss, J. Scott ; Spotts, Crystal ; Davis, Larry ; Davis, Aaron ; Fox, Peter T ; Soni, Poonam ; Blomgren, Michael ; Silverman, Andrew ; Riley, Glyndon. / Exploratory randomized clinical study of pagoclone in persistent developmental stuttering : The examining pagoclone for persistent developmental stuttering study. In: Journal of Clinical Psychopharmacology. 2010 ; Vol. 30, No. 1. pp. 48-56.
@article{14f7b3259f134646af5846d1c4a9783f,
title = "Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: The examining pagoclone for persistent developmental stuttering study",
abstract = "INTRODUCTION: Stuttering is a speech disorder in which the flow of speech is disrupted by repetitions, prolongation, and blocks of sounds, syllables, or words. No pharmacological treatments are approved for use in stuttering, and the most common form of treatment is speech therapy. This study was designed to assess the safety, tolerability, and effectiveness of pagoclone during 8 weeks of double-blind treatment followed by a 1-year open-label extension in patients who stutter. METHODS: An 8-week, multicenter, parallel-group, 2-arm, randomized (ratio 2:1 pagoclone-placebo), double-blind study with a 1-year open-label extension conducted at 16 US centers, including men and women aged 18 to 65 years who developed stuttering before 8 years of age. Twice-daily dosing with pagoclone (n = 88 patients) or matching placebo (n = 44 patients), with primary and secondary efficacy variables defined a priori, including Stuttering Severity Instrument Version 3 outcomes, clinician global impressions of improvement, and the change in the percentage of syllables stuttered. RESULTS: Pagoclone produced an average 19.4{\%} reduction in percentage of syllables stuttered compared with 5.1{\%} reduction for placebo. During open-label treatment, a 40{\%} reduction in the percent syllables stuttered was observed after 1 year of treatment with pagoclone. The most commonly reported adverse event during double-blind treatment was headache (12.5{\%} pagoclone patients, 6.8{\%} placebo patients). DISCUSSION: Pagoclone was effective in reducing symptoms of stuttering and was well tolerated. In light of its favorable tolerability profile, as well as consistency of effects across multiple efficacy variables, pagoclone may have potential as a pharmacological treatment of stuttering. LIMITATIONS: The main limitation of this study was the adequacy of the number of subjects who participated because this study was conducted as a pilot investigation. Furthermore, as this condition waxes and wanes, the assessment of stuttering within the clinic setting may not be an adequate reflection of the stuttering of the patients within the community.",
keywords = "Clinical trial, Pagoclone, Percent syllables stuttered, Stuttering",
author = "Gerald Maguire and David Franklin and Vatakis, {Nick G.} and Elena Morgenshtern and Timothey Denko and Yaruss, {J. Scott} and Crystal Spotts and Larry Davis and Aaron Davis and Fox, {Peter T} and Poonam Soni and Michael Blomgren and Andrew Silverman and Glyndon Riley",
year = "2010",
month = "2",
doi = "10.1097/JCP.0b013e3181caebbe",
language = "English (US)",
volume = "30",
pages = "48--56",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Exploratory randomized clinical study of pagoclone in persistent developmental stuttering

T2 - The examining pagoclone for persistent developmental stuttering study

AU - Maguire, Gerald

AU - Franklin, David

AU - Vatakis, Nick G.

AU - Morgenshtern, Elena

AU - Denko, Timothey

AU - Yaruss, J. Scott

AU - Spotts, Crystal

AU - Davis, Larry

AU - Davis, Aaron

AU - Fox, Peter T

AU - Soni, Poonam

AU - Blomgren, Michael

AU - Silverman, Andrew

AU - Riley, Glyndon

PY - 2010/2

Y1 - 2010/2

N2 - INTRODUCTION: Stuttering is a speech disorder in which the flow of speech is disrupted by repetitions, prolongation, and blocks of sounds, syllables, or words. No pharmacological treatments are approved for use in stuttering, and the most common form of treatment is speech therapy. This study was designed to assess the safety, tolerability, and effectiveness of pagoclone during 8 weeks of double-blind treatment followed by a 1-year open-label extension in patients who stutter. METHODS: An 8-week, multicenter, parallel-group, 2-arm, randomized (ratio 2:1 pagoclone-placebo), double-blind study with a 1-year open-label extension conducted at 16 US centers, including men and women aged 18 to 65 years who developed stuttering before 8 years of age. Twice-daily dosing with pagoclone (n = 88 patients) or matching placebo (n = 44 patients), with primary and secondary efficacy variables defined a priori, including Stuttering Severity Instrument Version 3 outcomes, clinician global impressions of improvement, and the change in the percentage of syllables stuttered. RESULTS: Pagoclone produced an average 19.4% reduction in percentage of syllables stuttered compared with 5.1% reduction for placebo. During open-label treatment, a 40% reduction in the percent syllables stuttered was observed after 1 year of treatment with pagoclone. The most commonly reported adverse event during double-blind treatment was headache (12.5% pagoclone patients, 6.8% placebo patients). DISCUSSION: Pagoclone was effective in reducing symptoms of stuttering and was well tolerated. In light of its favorable tolerability profile, as well as consistency of effects across multiple efficacy variables, pagoclone may have potential as a pharmacological treatment of stuttering. LIMITATIONS: The main limitation of this study was the adequacy of the number of subjects who participated because this study was conducted as a pilot investigation. Furthermore, as this condition waxes and wanes, the assessment of stuttering within the clinic setting may not be an adequate reflection of the stuttering of the patients within the community.

AB - INTRODUCTION: Stuttering is a speech disorder in which the flow of speech is disrupted by repetitions, prolongation, and blocks of sounds, syllables, or words. No pharmacological treatments are approved for use in stuttering, and the most common form of treatment is speech therapy. This study was designed to assess the safety, tolerability, and effectiveness of pagoclone during 8 weeks of double-blind treatment followed by a 1-year open-label extension in patients who stutter. METHODS: An 8-week, multicenter, parallel-group, 2-arm, randomized (ratio 2:1 pagoclone-placebo), double-blind study with a 1-year open-label extension conducted at 16 US centers, including men and women aged 18 to 65 years who developed stuttering before 8 years of age. Twice-daily dosing with pagoclone (n = 88 patients) or matching placebo (n = 44 patients), with primary and secondary efficacy variables defined a priori, including Stuttering Severity Instrument Version 3 outcomes, clinician global impressions of improvement, and the change in the percentage of syllables stuttered. RESULTS: Pagoclone produced an average 19.4% reduction in percentage of syllables stuttered compared with 5.1% reduction for placebo. During open-label treatment, a 40% reduction in the percent syllables stuttered was observed after 1 year of treatment with pagoclone. The most commonly reported adverse event during double-blind treatment was headache (12.5% pagoclone patients, 6.8% placebo patients). DISCUSSION: Pagoclone was effective in reducing symptoms of stuttering and was well tolerated. In light of its favorable tolerability profile, as well as consistency of effects across multiple efficacy variables, pagoclone may have potential as a pharmacological treatment of stuttering. LIMITATIONS: The main limitation of this study was the adequacy of the number of subjects who participated because this study was conducted as a pilot investigation. Furthermore, as this condition waxes and wanes, the assessment of stuttering within the clinic setting may not be an adequate reflection of the stuttering of the patients within the community.

KW - Clinical trial

KW - Pagoclone

KW - Percent syllables stuttered

KW - Stuttering

UR - http://www.scopus.com/inward/record.url?scp=74549123336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549123336&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3181caebbe

DO - 10.1097/JCP.0b013e3181caebbe

M3 - Article

C2 - 20075648

AN - SCOPUS:74549123336

VL - 30

SP - 48

EP - 56

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 1

ER -